Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KORU Medical Systems (KRMD) Cash from Financing Activities (2020 - 2025)

KORU Medical Systems (KRMD) has disclosed Cash from Financing Activities for 10 consecutive years, with $396330.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 5.84% to $396330.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$172158.0, a 18.47% increase, with the full-year FY2024 number at -$248533.0, down 13.55% from a year prior.
  • Cash from Financing Activities was $396330.0 for Q3 2025 at KORU Medical Systems, up from -$191964.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $2.2 million in Q1 2021 to a low of -$262226.0 in Q2 2022.
  • A 5-year average of $134785.5 and a median of -$160808.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 119.42% in 2021, then plummeted 32154.12% in 2022.
  • KORU Medical Systems' Cash from Financing Activities stood at -$133714.0 in 2021, then decreased by 8.89% to -$145603.0 in 2022, then dropped by 22.49% to -$178355.0 in 2023, then dropped by 20.95% to -$215716.0 in 2024, then surged by 283.73% to $396330.0 in 2025.
  • Per Business Quant, the three most recent readings for KRMD's Cash from Financing Activities are $396330.0 (Q3 2025), -$191964.0 (Q2 2025), and -$160808.0 (Q1 2025).